ESTRO 2023 - Abstract Book

S1294

Digital Posters

ESTRO 2023

Conclusion Despite varying regimens and treatment schedules (daily RT lasting several weeks to monthly systemic treatments) patients consistently used an ePRO to report their experiences. This systematic method of quantifying the patient voice compliments standard-of-care treatment by hastening the recognition of patient distress regardless of treatment modality and facilitates continuity of care. Finally, the ePROs wide, sustained use is a behavioral indicator that patients value its use during a vulnerable period in their cancer journey.

PO-1594 Optimizing palliative radiotherapy treatment in last 30 days of life

J.D. González 1

1 Hospital Universitario Arnau de Vilanova, Radiation Oncology, Lleida, Spain

Purpose or Objective 30-days mortality rate (30DMR) is known as an overtreatment endpoint for palliative patients. The recommended 30DMR is under 20%. In a previous analysis done in our center we found our 30DMR is 18.88%. We aimed to study if 30 and 15DMR could be related to primary tumor site and if this could be a factor in the decision making about what patients to offer a palliative radiotherapy treatment Materials and Methods We recorded the survival length in days from the end of palliative RT of patients treated from January to December 2021 at our institution. We also collected the primary tumor site of every treatment done. Data was obtained from ARIA electronic data base. Results 181 palliative treatments were performed, 143 patients were evaluable. Median age was 69 years-old. 57% were men and 43% women. Main treatment locations were: bone (30.77%), CNS (14.69%), lung (9%), colorectal (6.3%) and bladder (2.1%). The most common primary tumors treated were: lung (30.77%) colorectal (14.69%) breast (13.99%) prostate (9%) and gastroesophageal (6,3%) the rest of tumors encompassed the 23.08%. If we look at the cohort of patients that died in the first 30 days (18.88%) the primary tumor distribution was: Lung (44.44%) Rectal (14.81%) Breast (14.81%) Gastric (11.11%) Others (14.81%). In the analysis between primary sites the 15 and 30DMR were as follows: Lung (18.1% and 24.9%) Colorectal (0 and 26.6%), breast (10 and 20%), Prostate (0 and 0%) gastroesophageal (0 and 33.33%).